Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Syntimmune
5011
Syntimmune
Health Care
Technology
Biotechnology
Medical
Pharmaceuticals
Founded in 2013, Syntimmune is the worlds leader in the biology of the neonatal Fc receptor (FcRn). Syntimmune's lead program targets FcRn.
Suggest edits
Founded
2013
Raised
$84M
Follow us
Also headquartered in New York
Verizon
IBM
HBO
Bloomberg
Goldman Sachs
JPMorgan
Kickstarter
Wired
Morgan Stanley
The New York Times
Companies in the same industry
TearSolutions
Ark Biosciences
Metis Precision Medicine
Provia Laboratories
Egalet Corporation
MicuRx Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Ltd
Neuraltus Pharmaceuticals
molecular assemblies
Esperion Therapeutics
Alexa global traffic share
Overview
Funding
3
Add info
Latest funding
Show all
$50,000,000
Venture capital (Series B) - 2017
Partners Innovation Fund
Apple Tree Partners
Baxalta Ventures
$8,000,000
Venture capital (Series A) - 2016
Partners Innovation Fund
Apple Tree Partners
Baxalta Ventures
Team Size
1–10
Employees
I work here
Location
New York
,
United States
Headquarters
Explore New York
FinSMEs
Alexion To Acquire Syntimmune, for Up To $1.2 Billion
Health
PE HUB
| Apple Tree-backed Syntimmune appoints president and CEO
Strategy
Health
Xconomy
Syntimmune Snares $50M to Test Autoimmune Drug in Two Rare Diseases
Health
Science
$26,000,000
Venture capital (Series A)
VentureWire
The Daily Startup: Syntimmune Fights Autoimmune Diseases With New Funds
Funding
$26,000,000
Venture capital (Series A)
businesswire
Syntimmune Secures Second Tranche of $26 Million Series A Financing
Xconomy
NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree
Funding
Health
